We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Venn Life Sciences Holdings Plc | LSE:VENN | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.85 | 6.70 | 7.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMVENN
RNS Number : 3608V
Venn Life Sciences Holdings PLC
08 April 2019
8 April 2019
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Financing Update
Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces that Raglan Capital Limited, of whom Cathal Friel is a principal and owner, has subscribed for loan notes of GBP250,000 with a term of 13 months and a 8% coupon. The interest on the notes will be paid annually. The issue of the loan notes follows the previously announced financing of 11 December 2018 albeit on improved terms for the Company i.e. at a lower coupon and without any warrants or convertibility. The proceeds of the loan note will be applied to the Company's working capital.
Related Party Transaction
The subscription by Raglan Capital is considered a related party transaction for the purposes of Rule 13 of the AIM Rules for Companies. The Directors (other than Cathal Friel) consider, having consulted with Arden Partners, the Company's nominated adviser, that the terms of the subscription by Raglan Capital are fair and reasonable in so far as its Shareholders are concerned.
Enquiries:
Venn Life Sciences Holdings Plc Tel: +353 1 5499 341
Tony Richardson, Chief Executive Officer
Arden Partners (Nominated Advisor and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer
Davy (ESM Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Fergal Meegan / Matthew de Vere White (Corporate Finance)
About Venn Life Sciences
Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.
Further information in relation to Venn Life Sciences www.vennlifesciences.com
Venn life Science: getintouch@vennlife.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
UPDLFFLISFIDIIA
(END) Dow Jones Newswires
April 08, 2019 02:00 ET (06:00 GMT)
1 Year Venn Life Sciences Chart |
1 Month Venn Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
